Epstein-Barr virus infection and persistence in nasopharyngeal epithelial cells

Chinese Journal of Cancer

Volumn 33, Issue 11, 2014, Pages 549-555

  Tsang, Chi Man ^a   Deng, Wen ^a   Yip, Yim Ling ^a   Zeng, Mu Sheng ^b   Lo, Kwok Wai ^c   Tsao, Sai Wah ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Epithelial cells; Epstein Barr virus; Integrins; Latency; Nasopharyngeal carcinoma

Indexed keywords

CD11B ANTIGEN; COMPLEMENT RECEPTOR; CYCLIN D1; EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN 2; IMMEDIATE EARLY PROTEIN BZLF1; INTEGRIN; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; MICRORNA; MYOCYTE ENHANCER FACTOR 2; PROTEIN P16; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA1; VIRUS GLYCOPROTEIN;

B LYMPHOCYTE; CANCER CELL; DISEASE ASSOCIATION; EPISOME; EPITHELIUM CELL; EPSTEIN BARR VIRUS INFECTION; GENE DELETION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; LATENT VIRUS INFECTION; MEMBRANE FUSION; NASOPHARYNX CARCINOMA; NONHUMAN; OROPHARYNX; PATHOGENESIS; PERSISTENT VIRUS INFECTION; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; UNDIFFERENTIATED CARCINOMA; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS GENE; VIRUS TRANSMISSION; CELL CULTURE; CELL TRANSFORMATION; EPSTEIN BARR VIRUS; NASOPHARYNX; NASOPHARYNX TUMOR; PRECANCER;

CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; EPITHELIAL CELLS; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; NASOPHARYNGEAL NEOPLASMS; NASOPHARYNX; PRECANCEROUS CONDITIONS;

EID: 84909942991     PISSN: None     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.014.10169     Document Type: Review

References (67)

1. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet, 1964,1:702-703.
2. Diehl V, Henle G, Henle W, et al. Demonstration of a herpes group virus in cultures of peripheral leukocytes from patients with infectious mononucleosis. J Virol, 1968,2:663-669.
3. Rickinson AB, Kieff E. Epstein-Barr virus. Fields BN, Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott-Raven Publishers, 1996:2397-2446.
4. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer, 2004,4:757-768.
5. Niedobitek G, Agathanggelou A, Nicholls JM. Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Semin Cancer Biol, 1996,7:165-174.
6. Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer, 2011,30:114-119.
7. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol, 2002,12:431-441.
8. Tsao SW, Tsang CM, Pang PS, et al. The biology of EBV infection in human epithelial cells. Semin Cancer Biol, 2012,22:137-143.
9. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell, 2004,5:423-428.
10. Chen J, Fu L, Zhang LY, et al. Tumor suppressor genes on frequently deleted chromosome 3p in nasopharyngeal carcinoma. Chin J Cancer, 2012,31:215-222.
11. Nemerow GR, Wolfert R, McNaughton ME, et al. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol, 1985,55:347-351.
12. Hutt-Fletcher LM, Lake CM. Two Epstein-Barr virus glycoprotein complexes. Curr Top Microbiol Immunol, 2001,258:51-64.
13. Borza CM, Hutt-Fletcher LM. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med, 2002,8:594-599.
14. Hutt-Fletcher L. EBV entry and epithelial infection. Robertson ES ed. Epstein-Barr virus. Casister: Academic Press, 2005:359-378.
15. Li QX, Young LS, Niedobitek G, et al. Epstein-Barr virus infection and replication in a human epithelial cell system. Nature, 1992,356:347-350.
16. Knox PG, Li QX, Rickinson AB, et al. In vitro production of stable Epstein-Barr virus-positive epithelial cell clones which resemble the virus: cell interaction observed in nasopharyngeal carcinoma. Virology, 1996,215:40-50.
17. Sixbey JW, Yao QY. Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism. Science, 1992,255:1578-1580.
18. Lin CT, Lin CR, Tan GK, et al. The mechanism of Epstein-Barr virus infection in nasopharyngeal carcinoma cells. Am J Pathol, 1997,150:1745-1756.
19. Wu HC, Lin YJ, Lee JJ, et al. Functional analysis of EBV in nasopharyngeal carcinoma cells. Lab Invest, 2003,83:797-812.
20. Imai S, Nishikawa J, Takada K. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol, 1998,72:4371-4378.
21. Yoshiyama H, Imai S, Shimizu N, et al. Epstein-Barr virus infection of human gastric carcinoma cells: implication of the existence of a new virus receptor different from CD21. J Virol, 1997,71:5688-5691.
22. Shannon-Lowe CD, Neuhierl B, Baldwin G, et al. Resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells. Proc Natl Acad Sci U S A, 2006,103:7065-7070.
23. Shannon-Lowe C, Rowe M. Epstein-Barr virus infection of polarized epithelial cells via the basolateral surface by memory B cellmediated transfer infection. PLoS Pathog, 2011,7:e1001338.
24. Chesnokova LS, Hutt-Fletcher LM. Fusion of Epstein-Barr virus with epithelial cells can be triggered by αvβ5 in addition to αvβ6 and αvβ8, and integrin binding triggers a conformational change in glycoproteins gHgL. J Virol, 2011,85:13214-13223.
25. Chesnokova LS, Nishimura SL, Hutt-Fletcher LM. Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins αvβ6 or αvβ8. Proc Natl Acad Sci U S A, 2009,106:20464-20469.
26. Tugizov SM, Berline JW, Palefsky JM. Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med, 2003,9:307-314.
27. Hutt-Fletcher LM, Chesnokova LS. Integrins as triggers of Epstein-Barr virus fusion and epithelial cell infection. Virulence, 2010,1:395-398.
28. Tsai MH, Raykova A, Klinke O, et al. Spontaneous lytic replication and epitheliotropism define an Epstein-Barr virus strain found in carcinomas. Cell Rep, 2013,5:458-470.
29. Ma SD, Yu X, Mertz JE, et al. An Epstein-Barr virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. J Virol, 2012,86:7976-7987.
30. Yip YL, Pang PS, Deng W, et al. Efficient immortalization of primary nasopharyngeal epithelial cells for EBV infection study. PloS One, 2013,8:e78395.
31. Tsang CM, Yip YL, Lo KW, et al. Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells. Proc Natl Acad Sci U S A, 2012,109:E3473-E3482.
32. Tsang CM, Zhang G, Seto E, et al. Epstein-Barr virus infection in immortalized nasopharyngeal epithelial cells: regulation of infection and phenotypic characterization. Int J Cancer, 2010,127:1570-1583.
33. Klein E, Kis LL, Klein G. Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene, 2007,26:1297-1305.
34. Maruo S, Zhao B, Johannsen E, et al. Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci U S A, 2011,108:1919-1924.
35. Woisetschlaeger M, Jin XW, Yandava CN, et al. Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection. Proc Natl Acad Sci U S A, 1991,88:3942-3946.
36. Yoo L, Speck SH. Determining the role of the Epstein-Barr virus Cp EBNA2-dependent enhancer during the establishment of latency by using mutant and wild-type viruses recovered from cottontop marmoset lymphoblastoid cell lines. J Virol, 2000,74:11115-11120.
37. Shannon-Lowe C, Adland E, Bell AI, et al. Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. J Virol, 2009,83:7749-7760.
38. Pathmanathan R, Prasad U, Sadler R, et al. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med, 1995,333:693-698.
39. Lo KW, Chung GT, To KF. Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Semin Cancer Biol, 2012,22:79-86.
40. Li HM, Man C, Jin Y, et al. Molecular and cytogenetic changes involved in the immortalization of nasopharyngeal epithelial cells by telomerase. Int J Cancer, 2006,119:1567-1576.
41. Lo KW, Huang DP. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol, 2002,12:451-462.
42. Song LB, Zeng MS, Liao WT, et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res, 2006,66:6225-6232.
43. Herrmann K, Frangou P, Middeldorp J, et al. Epstein-Barr virus replication in tongue epithelial cells. J Gen Virol, 2002,83:2995-2998.
44. Nishi K, Inoue H, Schnier JB, et al. Cyclin D1 downregulation is important for permanent cell cycle exit and initiation of differentiation induced by anchorage-deprivation in human keratinocytes. J Cell Biochem, 2009,106:63-72.
45. Latella L, Sacco A, Pajalunga D, et al. Reconstitution of Cyclin D1-associated kinase activity drives terminally differentiated cells into the cell cycle. Mol Cell Biol, 2001,21:5631-5643.
46. Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol, 2005,79:1296-1307.
47. MacCallum P, Karimi L, Nicholson LJ. Definition of the transcription factors which bind the differentiation responsive element of the Epstein-Barr virus BZLF1 Z promoter in human epithelial cells. J Gen Virol, 1999,80:1501-1512.
48. Wille CK, Nawandar DM, Panfil AR, et al. Viral genome methylation differentially affects the ability of BZLF1 versus BRLF1 to activate Epstein-Barr virus lytic gene expression and viral replication. J Virol, 2013,87:935-950.
49. Kenney SC, Mertz JE. Regulation of the latent-lytic switch in Epstein-Barr virus. Semin Cancer Biol, 2014,26:60-68.
50. Li LL, Shu XS, Wang ZH, et al. Epigenetic disruption of cell signaling in nasopharyngeal carcinoma. Chin J Cancer, 2011,30:231-239.
51. Tempera I, Lieberman PM. Epigenetic regulation of EBV persistence and oncogenesis. Semin Cancer Biol, 2014,26:22-29.
52. Ramasubramanyan S, Kanhere A, Osborn K, et al. Genome-wide analyses of Zta binding to the Epstein-Barr virus genome reveals interactions in both early and late lytic cycles and an epigenetic switch leading to an altered binding profile. J Virol, 2012,86:12494-12502.
53. Bergbauer M, Kalla M, Schmeinck A, et al. CpG-methylation regulates a class of Epstein-Barr virus promoters. PLoS Pathog, 2010,6:e1001114.
54. Frappier L. Role of EBNA1 in NPC tumourigenesis. Semin Cancer Biol, 2012,22:154-161.
55. Yates J, Warren N, Reisman D, et al. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci U S A, 1984,81:3806-3810.
56. Lupton S, Levine AJ. Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus-derived plasmids in human cells. Mol Cell Biol, 1985,5:2533-2542.
57. Krysan PJ, Haase SB, Calos MP. Isolation of human sequences that replicate autonomously in human cells. Mol Cell Biol, 1989,9:1026-1033.
58. Lee MA, Diamond ME, Yates JL. Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus. J Virol, 1999,73:2974-2982.
59. Rawlins DR, Milman G, Hayward SD, et al. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell, 1985,42:859-868.
60. Reisman D, Yates J, Sugden B. A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cisacting components. Mol Cell Biol, 1985,5:1822-1832.
61. Nanbo A, Sugden A, Sugden B. The coupling of synthesis and partitioning of EBV's plasmid replicon is revealed in live cells. EMBO J, 2007,26:4252-4262.
62. Sivachandran N, Thawe NN, Frappier L. Epstein-Barr virus nuclear antigen 1 replication and segregation functions in nasopharyngeal carcinoma cell lines. J Virol, 2011,85:10425-10430.
63. Ellis AL, Wang Z, Yu X, et al. Either ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner. J Virol, 2010,84:6139-6152.
64. Kraus RJ, Perrigoue JG, Mertz JE. ZEB negatively regulates the lytic-switch BZLF1 gene promoter of Epstein-Barr virus. J Virol, 2003,77:199-207.
65. Yu X, Wang Z, Mertz JE. ZEB1 regulates the latent-lytic switch in infection by Epstein-Barr virus. PLoS Pathog, 2007,3:e194.
66. Ellis-Connell AL, Iempridee T, Xu I, et al. Cellular microRNAs 200b and 429 regulate the Epstein-Barr virus switch between latency and lytic replication. J Virol, 2010,84:10329-10343.
67. Lin Z, Wang X, Fewell C, et al. Differential expression of the miR-200 family microRNAs in epithelial and B cells and regulation of Epstein-Barr virus reactivation by the miR-200 family member miR-429. J Virol, 2010,84:7892-7897.